Cognition Therapeutics, Inc. ISIN: US19243B1026 Forum: Aktien User: Solix

The FDA has indicated that two six-month Phase 3 studies could support a new drug application, allowing for faster enrollment and more cost-effective trials. With a market capitalization of $80.70 million, CGTX has experienced significant volatility, trading between $0.22 and $1.29 over the past year. According to Benzinga Pro data, the neurodegeneration drug developer jumped 28.10% to $1.10 on Tuesday. Why It Matters: The Phase 3 program of Cognition will enroll adults with mild-to-moderate Alzheimer’s disease who demonstrate lower p-tau217 levels at screening. Previous Phase 2 SHINE study results showed Zervimesine arrested cognitive deterioration by 95% compared to placebo in this specific patient population. The enrichment strategy using plasma p-tau217 as a predictive biomarker aims to identify patients most likely to benefit from treatment. Cognition Therapeutics has received approximately $111 million in National Institutes of Health grant support for its zervimesine development programs. With a strong Momentum in the 82nd percentile, Benzinga’s Edge Stock Rankings indicate CGTX has a negative price trend across all time frames. Track the performance of other players in this segment.  Read Next:  Dow Surges 500 Points; US Core Inflation Rises To 3.1% Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. Photo courtesy: Tada Images via Shutterstock Disclaimer: This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision. Related News 12 Health Care Stocks Moving In Thursday's Intraday Session Benzinga · 08/14 19:06 200 views 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Benzinga · 08/13 14:08 189 views Why Sapiens International Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket Benzinga · 08/13 13:17 394 views

Gibt noch keine Neuigkeiten? Warum dann heute 22%?

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease

👀

😃💪🏻

Der Monatschart sieht recht gut aus 🤔

🙄

Sieht gut aus heute 😁

ℹ Cognition Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase. Das Unternehmen beschäftigt sich mit der Entdeckung und Entwicklung von niedermolekularen Therapeutika, die auf altersbedingte degenerative Erkrankungen und Störungen des zentralen Nervensystems (ZNS) und der Netzhaut abzielen. Es entwickelt eine Pipeline von niedermolekularen Produktkandidaten, die auf den Sigma-2-Rezeptor (S2R)-Komplex abzielen, einen Regulator der zellulären Schadensreaktion bei Krankheiten wie der Alzheimer-Krankheit (AD), trockener altersbedingter Makuladegeneration (dry AMD), geografischer Atrophie (GA) und anderen Erkrankungen. Der führende Produktkandidat CT1812 ist ein oral verabreichter, niedermolekularer Antagonist, der die Blut-Hirn-Schranke durchdringt und selektiv an den S2R-Komplex bindet. Durch seine Modulation werden die normale Funktion der Synapsen sowie wichtige zelluläre Prozesse wie Autophagie, Cholesterinbiosynthese, Vesikeltransport, Progesteronsignalisierung und Rezeptorstabilisierung an der Zelloberfläche wiederhergestellt. Mitarbeiterzahl : 25 Personen.